NCT04573062

Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

Recruiting now Last updated 13 March 2026

What this trial tests

trial in Post-Coronavirus Disease 19 in 1,590 participants. Currently enrolling.

Timeline

2 January 2022

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	National Institute of Neurological Disorders and Stroke (NINDS)
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,590
Start date	2 January 2022
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Conditions studied

• Post-Coronavirus Disease 19 — all drugs for Post-Coronavirus Disease 19 →

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Who can join

Adults 18 to 100, any sex, with Post-Coronavirus Disease 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

People who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover from COVID-19. They will also use the data to help create future studies to understand why some people do not fully recover.

Objective:

To learn more about the range and timing of symptoms that people have before, during, and after COVID-19 infection.

Eligibility:

People ages 18 and older who can give documentation of a positive COVID-19 or antibody test.

Design:

Participants will be screened with a telephone interview. It will take 15 minutes. They will provide their COVID-19 test results and medical records.

Participants will complete a second telephone interview. It will take 30 60 minutes. They will also take online surveys every 3 months for 3 years.

The interview and surveys will ask participants about their health before they got COVID-19, what happened while they had COVID-19, and what their recovery has been like.

Participants will get log-in data to take the online surveys. Completing all of the surveys the first time may take up to 3 hours. Follow-up surveys will take up to 30 minutes. Participants do not have to complete the surveys in one sitting. They will be able to save their progress and finish the surveys later.

Participants may be contacted to take part in other research studies.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Post-acute COVID-19 syndrome.
   Nalbandian A, Sehgal K, Gupta A, Madhavan MV, et al · · 2021 · cited 3355× · PMID 33753937 · DOI 10.1038/s41591-021-01283-z
2. Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection.
   Mina Y, Enose-Akahata Y, Hammoud DA, Videckis AJ, et al · · 2023 · cited 39× · PMID 37147136 · DOI 10.1212/nxi.0000000000200097
3. Procedural Motor Memory Deficits in Patients With Long-COVID.
   Hayward W, Buch ER, Norato G, Iwane F, et al · · 2024 · cited 6× · PMID 38237090 · DOI 10.1212/wnl.0000000000208073
4. Post-exertional malaise in Long COVID: subjective reporting versus objective assessment.
   Stussman B, Camarillo N, McCrossin G, Stockman M, et al · · 2025 · cited 4× · PMID 40337174 · DOI 10.3389/fneur.2025.1534352
5. Central noradrenergic deficiency in post-infectious chronic fatigue: neurobehavioral correlates.
   Aregawi L, Walitt B, Sullivan P, Norato G, et al · · 2026 · PMID 42205163 · DOI 10.1093/braincomms/fcag173
6. Prevalence and severity of neurologic symptoms in Long-COVID and the role of pre-existing conditions, hospitalization, and mental health.
   Huff HV, Roberts H, Bartrum E, Norato G, et al · · 2025 · PMID 40635708 · DOI 10.3389/fneur.2025.1562084